Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock?
AGEN Early Access Revenues Signal a New Path Ahead of Approval
Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.
Is Agenus Stock a Hold Amid Valuation and Funding Risks?
AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning.
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC
Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early survival signals translate into a pivotal win.
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?
Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.
How Agenus' Pipeline Progress Unlock Its Next Growth Phase
AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.
Agenus: Weighing The Clinical Progress Against The Company's Cash
Agenus: Weighing The Clinical Progress Against The Company's Cash
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell?
Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive.
Agenus (AGEN) Q1 Earnings and Revenues Miss Estimates
Agenus (AGEN) came out with quarterly earnings of $1.02 per share, missing the Zacks Consensus Estimate of $2.1 per share. This compares to a loss of $1.03 per share a year ago.
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
Here is how Agenus (AGEN) and Align Technology (ALGN) have performed compared to their sector so far this year.
Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Agenus (AGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Techne's Q3 Earnings on Deck: What's in Store for the Stock?
TECH gears up for Q3 results with modest revenue growth expected as biotech funding trends and product momentum shape the outlook.
